FAM134B oligomerization drives endoplasmic reticulum membrane scission for ER-phagy
EMBO JOURNAL
Authors: Jiang, Xiao; Wang, Xinyi; Ding, Xianming; Du, Mengjie; Li, Boran; Weng, Xialian; Zhang, Jingzi; Li, Lin; Tian, Rui; Zhu, Qi; Chen, She; Wang, Liang; Liu, Wei; Fang, Lei; Neculai, Dante; Sun, Qiming
Abstract
Degradation of endoplasmic reticulum (ER) by selective autophagy (ER-phagy) is crucial for ER homeostasis. However, it remains unclear how ER scission is regulated for subsequent autophagosomal sequestration and lysosomal degradation. Here, we show that oligomerization of ER-phagy receptor FAM134B (also referred to as reticulophagy regulator 1 or RETREG1) through its reticulon-homology domain is required for membrane fragmentation in vitro and ER-phagy in vivo. Under ER-stress conditions, activated CAMK2B phosphorylates the reticulon-homology domain of FAM134B, which enhances FAM134B oligomerization and activity in membrane fragmentation to accommodate high demand for ER-phagy. Unexpectedly, FAM134B G216R, a variant derived from a type II hereditary sensory and autonomic neuropathy (HSAN) patient, exhibits gain-of-function defects, such as hyperactive self-association and membrane scission, which results in excessive ER-phagy and sensory neuron death. Therefore, this study reveals a mechanism of ER membrane fragmentation in ER-phagy, along with a signaling pathway in regulating ER turnover, and suggests a potential implication of excessive selective autophagy in human diseases.
Combination of angiotensin II and L-N-G-nitroarginine methyl ester exacerbates mitochondrial dysfunction and oxidative stress to cause heart failure
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
Authors: Hamilton, Dale J.; Zhang, Aijun; Li, Shumin; Cao, Tram N.; Smith, Jessie A.; Vedula, Indira; Cordero-Reyes, Andrea M.; Youker, Keith A.; Torre-Amione, Guillermo; Gupte, Anisha A.
Abstract
Mitochondrial dysfunction has been implicated as a cause of energy deprivation in heart failure (HF). Herein, we tested individual and combined effects of two pathogenic factors of nonischemic HF, inhibition of nitric oxide synthesis [with L-N-G-nitroarginine methyl ester (L-NAME)] and hypertension [with angiotensin II (AngII)], on myocardial mitochondrial function, oxidative stress, and metabolic gene expression. L-NAME and AngII were administered individually and in combination to mice for 5 wk. Although all treatments increased blood pressure and reduced cardiac contractile function, the L-NAME + AngII group was associated with the most severe HF, as characterized by edema, hypertrophy, oxidative stress, increased expression of Nppa and Nppb, and decreased expression of Atp2a2 and Camk2b. L-NAME + AngII-treated mice exhibited robust deterioration of cardiac mitochondrial function, as observed by reduced respiratory control ratios in subsarcolemmal mitochondria and reduced state 3 levels in interfibrillar mitochondria for complex I but not for complex II substrates. Cardiac myofibrils showed reduced ADP-supported and oligomycin-inhibited oxygen consumption. Mitochondrial functional impairment was accompanied by reduced mitochondrial DNA content and activities of pyruvate dehydrogenase and complex I but increased H2O2 production and tissue protein carbonyls in hearts from AngII and L-NAME + AngII groups. Microarray analyses revealed the majority of the gene changes attributed to the L-NAME + AngII group. Pathway analyses indicated significant changes in metabolic pathways, such as oxidative phosphorylation, mitochondrial function, cardiac hypertrophy, and fatty acid metabolism in L-NAME + AngII hearts. We conclude that L-NAME + AngII is associated with impaired mitochondrial respiratory function and increased oxidative stress compared with either L-NAME or AngII alone, resulting in nonischemic HF.